EXHIBIT 31.1

CERTIFICATION PURSUANT TO SECTION 302 OF
THE

SARBANES-OXLEY ACT OF 2002



I, William F. Donovan, M.D., Chief Executive
Officer of Spine Pain Management, Inc., certify that:



|1. | I have reviewed this quarterly report on Form 10-Q of Spine Pain Management, Inc. for the quarter ended June 30, 2012;
|-- | ----------------------------------------------------------------------------------------------------------------------



|2. | Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
|-- | ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------



|3. | Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the issuer as of, and for, the periods presented in this report;
|-- | -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------



|4. | The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15 (e) and 15d- 15 (e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
|-- | ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------



(a) Designed such disclosure controls and
procedures, or caused such disclosure controls and procedures to be designed under my supervision, to ensure that material information
relating to the issuer, including its consolidated subsidiaries, is made known to us by others within those entities, particularly
during the period in which this report is being prepared;



(b) Designed such internal control over
financial reporting, or caused such internal control over financial reporting to be designed under my supervision, to provide reasonable
assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in
accordance with generally accepted accounting principles;



(c) Evaluated the effectiveness of the
issuer's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure
controls and procedures, as of the end of the period covered by this report based on such evaluation; and



(d) Disclosed in this report any change
in the issuer's internal control over financial reporting that occurred during the issuer's most recent fiscal year that has materially
affected, or is reasonably likely to materially affect, the issuer's internal control over financial reporting; and



|5. | I have disclosed, based on my most recent evaluation of internal control over financial reporting, to the issuer's independent registered public accounting firm and the audit committee of the issuer's board of directors (or persons performing the equivalent functions):
|-- | -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------



(a) All significant deficiencies and material
weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect
the issuer's ability to record, process, summarize and report financial information; and



(b) Any fraud, whether or not material,
that involves management or other employees who have a significant role in the issuer's internal control over financial reporting.



|Date: August 10, 2012 | By:                                                   | /s/ William F. Donovan, M.D.
|--------------------- | ----------------------------------------------------- | ----------------------------
|                      | William F. Donovan, M.D.                             
|                      | Chief Executive Officer (Principal Executive Officer)